Loading the company…
Loading the company…
㈜에프앤디넷
English name as filed with DART, Korea’s corporate disclosure system · Correct the English name ›
Last updated 2026-11-02 · Korean page ›
Verification level — how far we have checked
L0 · Public records — NPS workforce · filed financials · patents — public data
A company based in Seoul, founded in 2004. Industry: Wholesale & Retail. Revenue for 2025 was ₩57.9bn. It has 302 employees enrolled in the National Pension Service (as of Aug 2026). It is externally audited; the latest audit opinion is “Unqualified”.
Loading…
Latest filing 2020-01-30 · latest registration 2024-12-18 · newest first
본 발명은 근육 질환의 예방, 치료 또는 근 기능 개선에 이용되는 익모초(Leonurus japonicus) 추출물 및 레오누린(leonurine)의 새로운 용도에 관한 것으로, 익모초 추출물 또는 레오누린을 함유하는 근육 질환 예방, 치료용 또는 근 기능 개선용 조성물에 관한 것이다. 본 발명의 조성물은 근 단백질 합성에 관여하는 mTOR의 활성을 증가시키고, 근 단백질 분해에 관여하는 MuRF1 및 atrogin-1의 발현을 억제하는 효과가 있으며 근육량을 증가시키고 및 근기능을 향상시켜, 긴장감퇴증(atony), 근위축증(muscular atrophy), 근이영양증(muscular dystrophy), 근육 퇴화, 근무력증, 악액질(cachexia) 및 근육감소증(sarcopenia) 등의 각종 근육 질환 예방, 치료 또는 개선에 유용하게 이용될 수 있다.
본 발명은 근육 질환의 예방, 치료 또는 근 기능 개선에 이용되는 약쑥(Artemisia argyi) 추출물의 새로운 용도에 관한 것으로, 약쑥 추출물을 함유하는 근육 질환 예방, 치료용 또는 근 기능 개선용 조성물에 관한 것이다. 본 발명의 조성물은 근 단백질 합성에 관여하는 mTOR의 활성을 증가시키고, 근 단백질 분해에 관여하는 MuRF1 및 atrogin-1의 발현을 억제하는 효과가 있는바, 긴장감퇴증(atony), 근위축증(muscular atrophy), 근이영양증(muscular dystrophy), 근육 퇴화, 근무력증, 악액질(cachexia) 및 근육감소증(sarcopenia)과 같은 질환의 예방 또는 치료에 유용하게 이용될 수 있다.
KIPO KIPRIS · checked 2026-10-15 · newest filings first · right: registration date (filing date if not yet registered) · 2 of 2 · titles and abstracts are in Korean as filed · click a row for details ▾
For now we hold public records only (National Pension Service · DART filings · patents · registers · press). When the company files material in our IR Room, it moves to L1. We do not score or rate companies — we only state how far we have checked.
| KRW bn | 2024 | 2025 |
|---|---|---|
| Revenue | 54.5 | 57.9 |
| Cost of sales | 17.5 | 20.5 |
| Gross profit (loss) | 36.9 | 37.4 |
| Selling, general and administrative expenses | 35.8 | 33.1 |
| Operating income (loss) | 1.2 | 4.3 |
| Non-operating income | 0.6 | 0.6 |
| Other gains | 0.3 | 0.3 |
| Finance income | 0.3 | 0.3 |
| Non-operating expenses | 0.8 | 0.7 |
| Other losses | 0.6 | 0.6 |
| Finance costs | 0.2 | 0.1 |
| Profit (loss) before tax | 1.0 | 4.1 |
| Income tax expense | (0.2) | 0.9 |
| Net income (loss) | 1.2 | 3.3 |
Revenue ₩57.9bn, up 6.3% YoY.
Operating margin 7.4% (prior 2.1%).
Net income ₩3.3bn.
Need more than is shown here? Ask for more information — full review report · valuation · executive teaser · IM · competitor analysis · due diligence. Tell us what you need and we will reply by email with scope, cost and timing.
Is this your company?
If anything here is wrong, tell us — we check it against the original and correct it. You do not need to join. If you would like your financials verified and this page completed, that is a separate process.
Headlines and links to public articles only · not checked by us (original ↗) · articles are in Korean — English headlines are our translation; where none is shown, “Read in English ›” opens a machine translation · “Broker view” is a forecast, not reported results · checked 2026-11-06